Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00984282 · ClinicalTrials.gov registry record · Phase 3

Nexavar® Versus Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer

A Phase 3 study of Thyroid Neoplasms, sponsored by Bayer.

Completed
Registry status
Phase 3
Development phase
417
Enrollment target
20
Study locations

NCT00984282 is a Phase 3 study of Thyroid Neoplasms that has completed, run by Bayer. The registered enrollment target is 417 participants, below the 780-participant average among 7 other Thyroid Neoplasms trials with a reported enrollment target (47% lower). The trial reports 20 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00984282, a Phase 3 study of Thyroid Neoplasms, has completed, sponsored by Bayer.

COMPLETED
Registry status
Phase 3
Development phase
417 participants
Enrollment target
20
Study locations

Study Summary

Trial of sorafenib versus placebo in the treatment of locally advanced or metastatic differentiated thyroid cancer refractory to radioiodine

Conditions Studied

Thyroid Neoplasms

Interventions

  • DRUG Placebo
  • DRUG Sorafenib (Nexavar, BAY43-9006)

Study Locations (20)

Other

  • - Vienna
  • - Bruxelles - Brussel
  • - Sofia
  • - Beijing
  • - Beijing
  • - Chengdu

California

  • - Los Angeles
  • - Stanford

Pennsylvania

  • - Philadelphia
  • - Pittsburgh

Connecticut

  • - New Haven

Georgia

  • - Atlanta

Massachusetts

  • - Boston

Michigan

  • - Ann Arbor

Missouri

  • - St Louis

Trial Details

FieldValue
Enrollment Target 417 participants
Start Date 2009-10-15
Est. Completion 2017-08-30
Phase Phase 3

Sponsor

Bayer

591 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00984282

The ClinicalTrials.gov registry entry for NCT00984282 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 417 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 780-participant average among 7 other Thyroid Neoplasms trials with a reported enrollment target (47% lower). The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Thyroid Neoplasms appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT00984282 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Other, California, Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT00984282 about?

NCT00984282 is a clinical study titled "Nexavar® Versus Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer". Trial of sorafenib versus placebo in the treatment of locally advanced or metastatic differentiated thyroid cancer refractory to radioiodine

What is the current status of trial NCT00984282?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 417 participants. The study started on 2009-10-15. Estimated completion is 2017-08-30.

What conditions does trial NCT00984282 study?

This clinical trial studies the following conditions: Thyroid Neoplasms.

What interventions are being tested in trial NCT00984282?

The interventions under investigation include: Placebo (DRUG), Sorafenib (Nexavar, BAY43-9006) (DRUG).

Who is sponsoring clinical trial NCT00984282?

This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00984282 being conducted?

This trial has 20 study locations across California, Connecticut, Georgia, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Thyroid Neoplasms

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Thyroid Neoplasms

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.